(PROK) ProKidney - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: (N/A)

Cell Therapy, Kidney Disease, Diabetes, Rilparencel

PROK EPS (Earnings per Share)

EPS (Earnings per Share) of PROK over the last years for every Quarter: "2020-12": -0.07, "2021-03": -0.36, "2021-06": -0.4, "2021-09": -0.54, "2021-12": -0.43, "2022-03": -2.12, "2022-06": -0.36, "2022-09": -0.19, "2022-12": -0.4, "2023-03": -0.16, "2023-06": -0.14, "2023-09": -0.18, "2023-12": -0.1, "2024-03": -0.16, "2024-06": -0.16, "2024-09": -0.14, "2024-12": -0.17, "2025-03": -0.13,

PROK Revenue

Revenue of PROK over the last years for every Quarter: 2020-12: null, 2021-03: null, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0.337595, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 4.494, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.076, 2025-03: 0.23,

Description: PROK ProKidney

ProKidney Corp. is a clinical-stage biotechnology company pioneering a cell therapy platform to treat various chronic kidney diseases. The companys lead candidate, rilparencel, is an autologous selected renal cells (SRC) therapy currently in Phase 3 and Phase 2 trials for patients with moderate to severe chronic kidney disease and diabetes. With a cryopreserved version of rilparencel in development, the company is poised to advance its clinical programs and potentially revolutionize the treatment landscape for chronic kidney diseases.

From a market perspective, ProKidney Corp.s common stock (PROK) is listed on NASDAQ, providing a liquid market for investors. As a biotechnology company, ProKidney operates in a highly competitive and innovative sector, with a strong focus on research and development. The companys headquarters in Winston-Salem, North Carolina, is strategically located near major research institutions, facilitating collaboration and talent acquisition.

Analyzing the technical data, the stocks recent price action indicates a potential bullish trend, with the 20-day SMA at $0.81 and the 50-day SMA at $0.79, both below the current price of $0.90. However, the 200-day SMA at $1.48 suggests a longer-term bearish trend. The ATR of 0.09 (9.80% volatility) indicates a relatively high level of price volatility. Considering the 52-week high of $2.99 and low of $0.51, the stock has shown significant price fluctuations.

From a fundamental perspective, ProKidney Corp.s market capitalization stands at $1.81 billion, with a Return on Equity (RoE) of 6.94%. The absence of a P/E ratio and forward P/E ratio is not surprising, given the companys focus on R&D and lack of commercialized products. As the company advances its clinical programs, investors will be watching for key milestones and updates on rilparencels progress.

Forecasting the stocks performance, we can anticipate potential price movements based on the technical and fundamental data. If rilparencel demonstrates positive results in its ongoing trials, we can expect a surge in the stock price, potentially breaking through the 200-day SMA at $1.48. Conversely, any setbacks or negative news may lead to a decline in the stock price, potentially testing the 52-week low of $0.51. With a high ATR and significant price fluctuations, investors should be prepared for potential volatility.

Additional Sources for PROK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

PROK Stock Overview

Market Cap in USD 1,812m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2022-07-12

PROK Stock Ratings

Growth Rating -75.1
Fundamental -
Dividend Rating 0.0
Rel. Strength 85.7
Analysts 4.14 of 5
Fair Price Momentum 0.34 USD
Fair Price DCF -

PROK Dividends

Currently no dividends paid

PROK Growth Ratios

Growth Correlation 3m -8.7%
Growth Correlation 12m -90.2%
Growth Correlation 5y -74.6%
CAGR 5y -21.97%
CAGR/Max DD 5y -0.23
Sharpe Ratio 12m -0.01
Alpha 31.28
Beta 3.737
Volatility 151.15%
Current Volume 343149.6k
Average Volume 20d 1102.8k
Stop Loss 3.6 (-3.5%)
What is the price of PROK shares?
As of July 09, 2025, the stock is trading at USD 3.73 with a total of 343,149,610 shares traded.
Over the past week, the price has changed by +560.18%, over one month by +280.61%, over three months by +630.08% and over the past year by +68.78%.
Is ProKidney a good stock to buy?
No, based on ValueRay´s Analyses, ProKidney (NASDAQ:PROK) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -75.09 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PROK is around 0.34 USD . This means that PROK is currently overvalued and has a potential downside of -90.88%.
Is PROK a buy, sell or hold?
ProKidney has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy PROK.
  • Strong Buy: 4
  • Buy: 0
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for PROK share price target?
According to our own proprietary Forecast Model, PROK ProKidney will be worth about 0.4 in July 2026. The stock is currently trading at 3.73. This means that the stock has a potential downside of -89.28%.
Issuer Target Up/Down from current
Wallstreet Target Price 4 7.2%
Analysts Target Price 4.7 25.2%
ValueRay Target Price 0.4 -89.3%